SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Stopped early · Phase 1
Conditions studied: Non Small Cell Lung Cancer, Solid Tumor
In brief
This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with nivolumab, a PD-1 antibody, in patients with NSCLC with a KRAS mutation. The study involves 2 parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion.
Key facts
- Study ID
- NCT05375084
- Run by
- Navire Pharma Inc., a BridgeBio company
- People needed
- 21
- Starts
- 2022-10-20
- Expected to finish
- 2024-07-15
- Last updated by the study team
- 2024-12-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Highlands Oncology — Springdale, Arkansas, United States
- Scripps Clinic Torrey Pines — La Jolla, California, United States
- Providence Medical Foundation — Santa Rosa, California, United States
- Memorial Regional Hospital (Memorial Cancer Institute) — Hollywood, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- Providence Portland Medical Center — Portland, Oregon, United States
- University of Pennsylvania (Abramson Cancer Center) — Philadelphia, Pennsylvania, United States
- Medical University of South Carolina (MUSC) - Hollings Cancer Center — Charleston, South Carolina, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Millennium Research and Clinical Development — Houston, Texas, United States
- NEXT Oncology — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.